I think you will find that Hovione is a private family company. It does not have to do press releases to keep shareholders informed.
Consider the skills of the two entities. IVX has demonstrated skills in clinical trials and dealing with regulating authorities, particularly in the USA. It owns the intellectual property around the active pharmaceutical agent (APA) in Zafirlukast. The missing ability is the ability to provide a formulation and device to allow inhaled delivery, which has prevented this for twenty years after very encouraging work by Zeneca, stopped by the banning of CFCs. Hovione has a patented device and the expertise for formulating the APA to allow delivery directly to the lung. Hovione desperately wants a product, or products, to deliver in their newly developed device. This looks like a partnership to me, and a real win/win situation.
IVX Price at posting:
2.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)